3653 results for «445»
3653 results
Metalfree PCI
21 May 2025 – From EuroPCR 2025
Explore metal-free PCI approaches emphasizing drug-coated balloon angioplasty and bioresorbable scaffold technologies. This session reviews angiographic outcomes in diffuse small vessel disease, bifurcation lesions, and acute myocardial infarction, alongside management strategies for restenosis post-DCB angioplasty, highlighting advancements in minimally invasive coronary interventions.
CTO, modern challenges and solutions
21 May 2025 – From EuroPCR 2025
Address modern challenges in chronic total occlusion (CTO) interventions with this session focusing on the latest technologies and techniques. Learn key procedural strategies and best practices through detailed case studies, and understand how evolving technology is shaping the future of CTO revascularization.
Overcoming resistant lesions in NSTEMI
21 May 2025 – From EuroPCR 2025
Address the challenges of resistant lesions in NSTEMI with this focused session. Learn from complex cases involving thrombus management using Penumbra systems and Guideliner, as well as strategies to overcome extensive calcification through multiple interventional tools, illustrating a stepwise approach to tackling difficult coronary lesions.
New evidence in the PFO closure
21 May 2025 – From EuroPCR 2025
Gain new insights into patent foramen ovale (PFO) closure with this session exploring age-related outcomes, risk of atrial arrhythmia, and patient selection improvements. Review various imaging approaches for assessing residual shunts and compare guidance techniques including TEE, fluoroscopy, and intracardiac echo from recent clinical registries.
Elixir Medical To Announce Late-Breaking Clinical Data at EuroPCR 2023 Session Featuring World’s First Transforming Coronary Artery Implant Designed to Restore Vessel Physiology and Function
09 May 2023
EuroPCR 2026: Elixir Medical's DynamX® bioadaptor demonstrates significantly lower event rates than drug-eluting stent in long-term follow-up, including reduction in cardiovascular death
19 May 2026
EuroPCR 2025: Late-breaking data demonstrate sustained significantly lower event rates with Elixir Medical’s DynamX® Bioadaptor over drug-eluting stent through three Years
21 May 2025
Positive 3-year results from FIRE Trial demonstrate Supraflex Cruz’s safety and efficacy in elderly heart attack patients
26 Sep 2025
A randomised, multicenter, non-inferiority comparison of intravascular lithotripsy and super-high-pressure non-compliant balloons for treatment of calcified and refractory coronary lesions - The VICTORY trial
27 Oct 2025
Mirvat Alasnag provides her take on the VICTORY trial presented by Matthias Bossard at TCT 2025 in San Francisco.
Author
Promising Safety and Efficacy Results for Supraflex Cruz in HBR Subset Analysis from FIRE Trial, with 1-Month DAPT
03 Nov 2023
Elixir Medical’s DynamX Bioadaptor demonstrates significant improvement over contemporary drug-eluting stent in patients with acute coronary syndrome and complex lesion subsets after six months
28 Oct 2024
EuroPCR 2024: Late-breaking data demonstrate significant clinical advantage of Elixir Medical’s DynamX bioadaptor over standard-of-care drug-eluting stent at two years
14 May 2024
EuroPCR 2023: Late-Breaking Clinical Data Demonstrate Elixir Medical’s DynamX Bioadaptor Restores Vessel Motion and Function with Better Effectiveness at 12 Months Compared to a Leading Drug-Eluting Stent (DES)
17 May 2023